alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › drug-discovery

drug-discovery

5 studies tagged drug-discovery, dated 2010-12-23 to 2025-05-02. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Alzheimer's disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids for disease modeling and drug discovery 2025-05-02
  2. Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development 2019-08-23
  3. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years? 2018-04-01

Studies

5 studies carry this tag.

Date range

2010 to 2025

Top journals

  • Bioorganic & medicinal chemistry letters 1
  • Expert opinion on drug discovery 1
  • Frontiers in pharmacology 1
  • Molecular neurobiology 1
  • Molecular psychiatry 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Alzheimer's disease patient brain extracts induce multiple pathologies in novel vascularized neuroimmune organoids for disease modeling and drug discovery

    ✓ Peer-reviewed alzhub usefulness score 48 out of 100. Molecular psychiatry 2025-05-02 Treatments

    Alzheimer's Disease (AD) is the most common cause of dementia, afflicting 55 million individuals worldwide, with limited treatment available.

  2. Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and Development

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Frontiers in pharmacology 2019-08-23 TREM2 and immune genetics

    Alzheimer's disease (AD) is a large and increasing unmet medical need with no disease-modifying treatment currently available.

  3. Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Expert opinion on drug discovery 2018-04-01 Treatments

    Areas covered: A massive scrutiny of AD-related PubMed publications (ps)(2013-2017) identified 42,053ps of which 8,380 (19.60%) were associated with AD treatments.

  4. Anti-amyloid Aggregation Activity of Natural Compounds: Implications for Alzheimer's Drug Discovery

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Molecular neurobiology 2015-06-23 Treatments

    Several plant-derived natural compounds are known to exhibit anti-amyloid aggregation activity which makes them attractive as potential therapies to treat Alzheimer's disease.

  5. Multitargeted drugs discovery: balancing anti-amyloid and anticholinesterase capacity in a single chemical entity

    ✓ Peer-reviewed alzhub usefulness score 36 out of 100. Bioorganic & medicinal chemistry letters 2010-12-23 Treatments

    Memoquin (1) is a lead compound multitargeted against Alzheimer's disease (AD).

All topic tags with their study counts